Literature DB >> 8725700

Pharmacokinetics of depot medroxyprogesterone acetate contraception.

D R Mishell1.   

Abstract

Depot medroxyprogesterone acetate (DMPA) is an aqueous suspension of 17-acetoxy 6-methyl progestin administered by intramuscular injection for long-term contraception. This highly effective injectable formulation of medroxyprogesterone acetate (MPA) has a prolonged duration of action since the progestin is released slowly from the muscle. MPA is detected in the serum within 30 minutes after an injection of 150 mg. Serum concentrations vary between individual women but generally plateau at about 1.0 ng/mL for about three months, after which there is a gradual decline. In some women, MPA can be detected in the serum for as long as nine months after a single injection of 150 mg. The circulating MPA initially inhibits the midcycle leutinizing hormone (LH) peak, but LH and follicle stimulating hormone (FSH) levels remain in the range of those for the luteal phase of a pretreatment control cycle. Since ovulation is inhibited, serum progesterone levels remain low (< 0.4 ng/mL) for several months following an injection of DMPA. When MPA levels fall below 0.1 ng/mL, ovulation resumes. Thus, return to fertility is delayed for several months if a woman wishes to conceive after receiving one or more injections of DMPA. Following an injection of DMPA, serum estradiol levels initially are in the early to midfollicular phase range (mean approximately 50 pg/nL). Serum estradiol levels begin to rise about four months after a single injection when MPA levels fall below 0.5 ng/mL. For women who have used DMPA for several years, serum estradiol levels range between 10 and 92 pg/mL, with mean levels of about 40 pg/mL. Despite these low levels of estradiol, hot flushes are a rare event, and the vaginal epithelium remains moist and well rugated. Women using DMPA for several years do not observe a change in breast size. DMPA causes the endometrium to become atrophic, with small, straight endometrial glands and decidualized stroma. The cervical mucus remains thick and viscid. DMPA is a very effective form of contraception because of its multiple mechanisms of action and slow release into the circulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725700

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  57 in total

1.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

Review 2.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

3.  Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection.

Authors:  Carley Tasker; Amy Davidow; Natalie E Roche; Theresa L Chang
Journal:  Immunohorizons       Date:  2017-11-01

4.  Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age.

Authors:  Christopher I Li; Elisabeth F Beaber; Mei Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone
Journal:  Cancer Res       Date:  2012-02-27       Impact factor: 12.701

5.  Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression.

Authors:  Annelie Tjernlund; Ann M Carias; Sonia Andersson; Susanna Gustafsson-Sanchez; Maria Röhl; Pernilla Petersson; Andrea Introini; Thomas J Hope; Kristina Broliden
Journal:  Biol Reprod       Date:  2015-01-14       Impact factor: 4.285

6.  Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.

Authors:  Amneris E Luque; Susan E Cohn; Jeong-Gun Park; Yoninah Cramer; Adriana Weinberg; Elizabeth Livingston; Karin L Klingman; Francesca Aweeka; D Heather Watts
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

7.  Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.

Authors:  Yasaman Zia; Jennifer H Tang; Lameck Chinula; Gerald Tegha; Frank Z Stanczyk; Athena P Kourtis
Journal:  Contraception       Date:  2019-07-30       Impact factor: 3.375

8.  Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.

Authors:  Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo
Journal:  Lancet HIV       Date:  2015-07       Impact factor: 12.767

9.  Hormonal contraceptive use and risk of HIV-1 disease progression.

Authors:  Renee Heffron; Nelly Mugo; Kenneth Ngure; Connie Celum; Deborah Donnell; Edwin Were; Helen Rees; James Kiarie; Jared M Baeten
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

Review 10.  Research gaps in defining the biological link between HIV risk and hormonal contraception.

Authors:  Kerry Murphy; Susan C Irvin; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2014-02-19       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.